AU739071C - Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system - Google Patents
Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous systemInfo
- Publication number
- AU739071C AU739071C AU29209/99A AU2920999A AU739071C AU 739071 C AU739071 C AU 739071C AU 29209/99 A AU29209/99 A AU 29209/99A AU 2920999 A AU2920999 A AU 2920999A AU 739071 C AU739071 C AU 739071C
- Authority
- AU
- Australia
- Prior art keywords
- central nervous
- nervous system
- transcription
- estradiol
- oestrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Selected steroids are used to produce pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system (CNS) without influencing other organs or systems. These steroids are characterised in that they have a selective, neurotropic, oestrogen-like transcription effect, unlike the systemically active natural and synthetic oestrogens, including 17a-estradiol. It has been surprisingly discovered that the selected steroids, when used according to the invention, selectively influence the transcription of oestrogen-dependent genes in the central nervous system and cause alterations of the corresponding physiological parameters; have transcription effects specific to the central nervous systems in doses which have no biological effects on the tissues of the reproductive system; have transcription effects specific to the central nervous system at doses at which neither 17b-estradiol nor 17a-estradiol have any effect; and do not influence the transcription of oestrogen-dependent genes in the central nervous system to a greater extent than the secondary 17b-estradiol.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19807264 | 1998-02-20 | ||
DE19807264 | 1998-02-20 | ||
DE1998121831 DE19821831A1 (en) | 1998-05-15 | 1998-05-15 | Selectively supplementing estrogen deficiency in the central nervous system, using 14,15-cyclopropano estrane steroid compounds |
DE19821831 | 1998-05-15 | ||
PCT/DE1999/000353 WO1999042108A1 (en) | 1998-02-20 | 1999-02-10 | Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2920999A AU2920999A (en) | 1999-09-06 |
AU739071B2 AU739071B2 (en) | 2001-10-04 |
AU739071C true AU739071C (en) | 2002-04-11 |
Family
ID=26044035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU29209/99A Ceased AU739071C (en) | 1998-02-20 | 1999-02-10 | Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1056460B1 (en) |
JP (1) | JP2002503694A (en) |
KR (1) | KR20010041107A (en) |
CN (1) | CN1291102A (en) |
AT (1) | ATE252388T1 (en) |
AU (1) | AU739071C (en) |
BG (1) | BG104689A (en) |
BR (1) | BR9909205A (en) |
CA (1) | CA2321498A1 (en) |
CZ (1) | CZ291764B6 (en) |
DE (1) | DE59907446D1 (en) |
EA (1) | EA002707B1 (en) |
EE (1) | EE03906B1 (en) |
HU (1) | HUP0100742A3 (en) |
ID (1) | ID27069A (en) |
IL (1) | IL137727A0 (en) |
IS (1) | IS5571A (en) |
NO (1) | NO20004153L (en) |
NZ (1) | NZ506049A (en) |
PL (1) | PL342313A1 (en) |
SK (1) | SK12152000A3 (en) |
TR (1) | TR200002400T2 (en) |
UA (1) | UA57830C2 (en) |
WO (1) | WO1999042108A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2253318T3 (en) | 2001-11-07 | 2006-06-01 | Schering Ag | IN VITRO LIGAND CROSSING OF THE STROGEN RECEIVER. |
CN112189624A (en) * | 2020-09-08 | 2021-01-08 | 山东第一医科大学(山东省医学科学院) | Method for constructing and identifying female AD model by using receptor gene silencing technology |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791099A (en) * | 1984-10-29 | 1988-12-13 | Chaovanee Aroonsakul | Method of treatment for central nervous system diseases such as Alzheimer's's disease |
WO1995012402A1 (en) * | 1993-11-05 | 1995-05-11 | University Of Florida Research Foundation, Incorporated | Estrogen compositions and method for neuroprotection |
WO1997003661A1 (en) * | 1995-07-24 | 1997-02-06 | University Of Florida Research Foundation, Incorporated | Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897389A (en) * | 1984-10-29 | 1990-01-30 | Chaovanee Aroonsakul | Treating central nervous system diseases |
DE4239946C2 (en) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estrane derivatives with a 14alpha, 15alpha-methylene group and process for their preparation |
DE4338314C1 (en) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage |
DE4429397C2 (en) * | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
DE19524937A1 (en) * | 1995-07-08 | 1997-01-09 | Jenapharm Gmbh | Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage and for drug substitution in men |
-
1999
- 1999-02-10 EP EP99910118A patent/EP1056460B1/en not_active Expired - Lifetime
- 1999-02-10 EE EEP200000477A patent/EE03906B1/en not_active IP Right Cessation
- 1999-02-10 CZ CZ20002938A patent/CZ291764B6/en not_active IP Right Cessation
- 1999-02-10 CA CA002321498A patent/CA2321498A1/en not_active Abandoned
- 1999-02-10 SK SK1215-2000A patent/SK12152000A3/en unknown
- 1999-02-10 CN CN99803170A patent/CN1291102A/en active Pending
- 1999-02-10 JP JP2000532123A patent/JP2002503694A/en not_active Abandoned
- 1999-02-10 TR TR2000/02400T patent/TR200002400T2/en unknown
- 1999-02-10 DE DE59907446T patent/DE59907446D1/en not_active Expired - Fee Related
- 1999-02-10 KR KR1020007009148A patent/KR20010041107A/en not_active Application Discontinuation
- 1999-02-10 BR BR9909205-0A patent/BR9909205A/en not_active IP Right Cessation
- 1999-02-10 NZ NZ506049A patent/NZ506049A/en unknown
- 1999-02-10 PL PL99342313A patent/PL342313A1/en unknown
- 1999-02-10 EA EA200000858A patent/EA002707B1/en not_active IP Right Cessation
- 1999-02-10 AT AT99910118T patent/ATE252388T1/en not_active IP Right Cessation
- 1999-02-10 HU HU0100742A patent/HUP0100742A3/en unknown
- 1999-02-10 IL IL13772799A patent/IL137727A0/en unknown
- 1999-02-10 AU AU29209/99A patent/AU739071C/en not_active Ceased
- 1999-02-10 ID IDW20001592A patent/ID27069A/en unknown
- 1999-02-10 WO PCT/DE1999/000353 patent/WO1999042108A1/en not_active Application Discontinuation
- 1999-10-02 UA UA2000095399A patent/UA57830C2/en unknown
-
2000
- 2000-07-24 IS IS5571A patent/IS5571A/en unknown
- 2000-08-15 BG BG104689A patent/BG104689A/en unknown
- 2000-08-18 NO NO20004153A patent/NO20004153L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791099A (en) * | 1984-10-29 | 1988-12-13 | Chaovanee Aroonsakul | Method of treatment for central nervous system diseases such as Alzheimer's's disease |
WO1995012402A1 (en) * | 1993-11-05 | 1995-05-11 | University Of Florida Research Foundation, Incorporated | Estrogen compositions and method for neuroprotection |
WO1997003661A1 (en) * | 1995-07-24 | 1997-02-06 | University Of Florida Research Foundation, Incorporated | Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells |
Also Published As
Publication number | Publication date |
---|---|
SK12152000A3 (en) | 2001-02-12 |
HUP0100742A2 (en) | 2001-09-28 |
EE03906B1 (en) | 2002-12-16 |
NO20004153D0 (en) | 2000-08-18 |
IS5571A (en) | 2000-07-24 |
EA200000858A1 (en) | 2001-04-23 |
BR9909205A (en) | 2000-11-14 |
CZ291764B6 (en) | 2003-05-14 |
BG104689A (en) | 2001-04-30 |
UA57830C2 (en) | 2003-07-15 |
WO1999042108A1 (en) | 1999-08-26 |
EA002707B1 (en) | 2002-08-29 |
DE59907446D1 (en) | 2003-11-27 |
HUP0100742A3 (en) | 2002-07-29 |
NZ506049A (en) | 2002-09-27 |
EP1056460B1 (en) | 2003-10-22 |
TR200002400T2 (en) | 2000-11-21 |
AU739071B2 (en) | 2001-10-04 |
ATE252388T1 (en) | 2003-11-15 |
CN1291102A (en) | 2001-04-11 |
ID27069A (en) | 2001-02-22 |
NO20004153L (en) | 2000-10-09 |
EP1056460A1 (en) | 2000-12-06 |
CZ20002938A3 (en) | 2001-01-17 |
JP2002503694A (en) | 2002-02-05 |
AU2920999A (en) | 1999-09-06 |
PL342313A1 (en) | 2001-06-04 |
CA2321498A1 (en) | 1999-08-26 |
IL137727A0 (en) | 2001-10-31 |
KR20010041107A (en) | 2001-05-15 |
EE200000477A (en) | 2001-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998027929A3 (en) | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | |
HUP0102483A2 (en) | Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol | |
WO1996019568A3 (en) | Stabilized ribozyme analogs | |
TR199800648A1 (en) | Medication system for two or more active ingredients. | |
AU5278899A (en) | 14,15-cyclopropanosteroids of the 19-norandrostane series, method for the production thereof and pharmaceutical preparations containing said compounds | |
AU2561195A (en) | Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding | |
MX9700223A (en) | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension. | |
AU7496894A (en) | Antiglucocorticoid steroids for the treatment of anxiety disorders | |
AU739071C (en) | Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system | |
BG102660A (en) | Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders | |
HUP9900612A2 (en) | Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies | |
EP1090639A3 (en) | Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator | |
GR3025872T3 (en) | Orally active derivatives of 1,3,5(10)-estratriene | |
WO2001085165A3 (en) | Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system | |
EP1003465A4 (en) | Prevention/retardation of hair growth | |
CA2248841A1 (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
CA2421302A1 (en) | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
WO2002022645A3 (en) | Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity | |
ATE215556T1 (en) | 11BETA-ARYL SUBSTITUTED 14,17-ETHANO ESTRATRIENES, PROCESS FOR PRODUCING THESE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICINAL PRODUCTS | |
Cadman | Roche brings new formulation of saquinavir to FDA. Food and Drug Administration | |
ATE189229T1 (en) | DIPEPTIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
ES2113106T3 (en) | ESTRES OF 14ALFA, 15ALFA-METHYLENE-ESTRADIOL WITH ADMINISTRABLE EFFECTS OF ESTROGEN. | |
MX9800697A (en) | Use of calendula glycosides for the treatment of psoriasis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20010911 |
|
FGA | Letters patent sealed or granted (standard patent) | ||
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20011018 |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |